Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome
暂无分享,去创建一个
P. Pasqualetti | C. Pozzilli | G. Lenzi | P. Pantano | F. Caramia | S. Di Legge | M. Piattella | P Pasqualetti | C Pozzilli | G L Lenzi | P Pantano | F Caramia | S Di Legge | I F Pestalozza | M C Piattella | I. Pestalozza
[1] David H. Miller,et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. , 2002, The New England journal of medicine.
[2] Ludwig Kappos,et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis , 1999, The Lancet.
[3] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[4] S. Reingold,et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.
[5] Marco Rovaris,et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.
[6] J. Simon. From enhancing lesions to brain atrophy in relapsing MS , 1999, Journal of Neuroimmunology.
[7] W. I. McDonald,et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis , 1994, Neurology.
[8] A. Thompson,et al. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI , 2001, Journal of neurology, neurosurgery, and psychiatry.
[9] G. Comi,et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.
[10] M. Horsfield,et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. , 1998, Brain : a journal of neurology.
[11] Jeffrey A. Cohen,et al. Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy , 2002, Multiple sclerosis.
[12] H Lechner,et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis , 1988, Neurology.
[13] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[14] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[15] F. Barkhof,et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a , 2003, Annals of neurology.
[16] A. Thompson,et al. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes , 2003, Annals of neurology.
[17] A. Thompson,et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[18] S. L. Galetta,et al. The utility of MRI in suspected MS , 2003, Neurology.
[19] Michael Wall,et al. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group , 2002, Neurology.